MorphoSys AG (MOR):企業の財務・戦略的SWOT分析

◆英語タイトル:MorphoSys AG (MOR) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14902
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥33,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used for the treatment of various types of cancers, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, solid tumors, eye disease, and other inflammatory diseases. Morphosys offers human combinatorial antibody library (HuCAL), a recombinant antibody technology which allows generation of therapeutic and diagnostic antibodies. The company provides clinical trials for cancer and inflammatory disorders. It also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products in China, Taiwan, Hong Kong, and Macao. Morphosys is headquartered in Munich, Germany.

MorphoSys AG Key Recent Developments

Feb 19,2019: Simon Moroney, CEO and co-founder of MorphoSys, announces his intention to retire
Nov 05,2018: MorphoSys announces third quarter 2018 results
Sep 17,2018: Morphosys and LEO Pharma expand strategic alliance to develop peptide-derived therapeutics
Sep 06,2018: MorphoSys to be listed in MDAX
Aug 02,2018: MorphoSys re­ports se­cond quarter 2018 fin­an­cial res­ults

This comprehensive SWOT profile of MorphoSys AG provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of MorphoSys AG including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

MorphoSys AG – Key Information
MorphoSys AG – Overview
MorphoSys AG – Key Employees
MorphoSys AG – Key Employee Biographies
MorphoSys AG – Key Operational Heads
MorphoSys AG – Major Products and Services
MorphoSys AG – History
MorphoSys AG – Company Statement
MorphoSys AG – Locations And Subsidiaries
MorphoSys AG – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

MorphoSys AG – Business Description
MorphoSys AG – Corporate Strategy
MorphoSys AG – SWOT Analysis
SWOT Analysis – Overview
MorphoSys AG – Strengths
MorphoSys AG – Weaknesses
MorphoSys AG – Opportunities
MorphoSys AG – Threats
MorphoSys AG – Key Competitors

Section 3 – Company Financial Performance Charts

MorphoSys AG – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

MorphoSys AG, Key Information
MorphoSys AG, Key Ratios
MorphoSys AG, Share Data
MorphoSys AG, Major Products and Services
MorphoSys AG, History
MorphoSys AG, Key Employees
MorphoSys AG, Key Employee Biographies
MorphoSys AG, Key Operational Heads
MorphoSys AG, Other Locations
MorphoSys AG, Subsidiaries
MorphoSys AG, Key Manufacturing facilities
MorphoSys AG, Key Competitors
MorphoSys AG, SWOT Analysis
MorphoSys AG, Ratios based on current share price
MorphoSys AG, Annual Ratios
MorphoSys AG, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

MorphoSys AG, Performance Chart
MorphoSys AG, Ratio Charts

★海外企業調査レポート[MorphoSys AG (MOR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Chori Co Ltd (8014):企業の財務・戦略的SWOT分析
    Chori Co Ltd (8014) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • First Pacific Co Ltd (142):企業の財務・戦略的SWOT分析
    First Pacific Co Ltd (142) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Monopar Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Monopar Therapeutics Inc (Monopar) is a biopharmaceutical company that develops drugs and drug combinations to improve clinical outcomes for cancer patients. The company’s pipeline product includes huATN-658, a humanized monoclonal antibody for the potential treatment of various cancers incl …
  • Interstate Hotels & Resorts Inc:企業の戦略・SWOT・財務情報
    Interstate Hotels & Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Interstate Hotels & Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Julius Baer Group Ltd.:戦略・SWOT・企業財務分析
    Julius Baer Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Julius Baer Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Knight-Swift Transportation Holdings Inc. (KNX):企業の財務・戦略的SWOT分析
    Knight-Swift Transportation Holdings Inc. (KNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • ELMOS Semiconductor AG (ELG):企業の財務・戦略的SWOT分析
    ELMOS Semiconductor AG (ELG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • JFE Holdings, Inc.:企業の戦略・SWOT・財務情報
    JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary JFE Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • SREI Infrastructure Finance Ltd:企業のM&A・事業提携・投資動向
    SREI Infrastructure Finance Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SREI Infrastructure Finance Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Connell Limited Partnership:企業の戦略・SWOT・財務分析
    Connell Limited Partnership - Strategy, SWOT and Corporate Finance Report Summary Connell Limited Partnership - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • MeiraGTx Holdings Plc (MGTX):製薬・医療:M&Aディール及び事業提携情報
    Summary MeiraGTx Holdings Plc (MeiraGTx) is an independent clinical-stage gene therapy company that focuses on the development of therapeutics for the treatment of eye, salivary gland and neurodegenerative diseases. The company’s pipeline of preclinical and research programs include AAV-CNGB3, for a …
  • SMCP S.A.S (SMCP):企業の財務・戦略的SWOT分析
    SMCP S.A.S (SMCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Microbion Corp-製薬・医療分野:企業M&A・提携分析
    Summary Microbion Corp (Microbion) is a clinical stage biopharmaceutical company which develops therapeutic products. The company develops products for the treatment of antibiotic-resistant infections and control of microbial biofilms. It develops environmentally responsible solutions to prevent mic …
  • QSR Brands (M) Holdings Sdn Bhd:企業の戦略・SWOT・財務情報
    QSR Brands (M) Holdings Sdn Bhd - Strategy, SWOT and Corporate Finance Report Summary QSR Brands (M) Holdings Sdn Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Tervita Corp:企業の戦略・SWOT・財務分析
    Tervita Corp - Strategy, SWOT and Corporate Finance Report Summary Tervita Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Novaliq GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops dermatological products, novel ophthalmic, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears a preserva …
  • Brunei National Petroleum Company Sendirian Berhad:石油・ガス:M&Aディール及び事業提携情報
    Summary Brunei National Petroleum Company Sendirian Berhad (PetroleumBRUNEI) is an oil and gas company that provides exploration and production of oil and gas. The company offers engineering, procurement, construction, installation, commissioning services, and others. It provides oilfield services, …
  • Neiman Marcus Group Ltd. LLC:企業の戦略的SWOT分析
    Neiman Marcus Group Ltd. LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Triumvira Immunologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Triumvira Immunologics Inc (Triumvira) is a biopharmaceutical company developing engineered T cell therapies for the treatment of multiple cancers. Its proprietary immuno-oncology platform T cell Antigen Coupler (TAC), enables natural T cell receptor to induce a controlled, tumor-specific re …
  • Yoshinoya Holdings Co Ltd
    Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆